AdAlta Chief Executive Officer Sam Cobb presented to the Morgans network in May 2018, providing an update on the company’s lead drug treatment AD-214 and an overview of the market opportunities for Idiopathic Pulmonary Fibrosis (IPF).
AdAlta Chief Executive Officer Sam Cobb presented to the Morgans network in May 2018, providing an update on the company’s lead drug treatment AD-214 and an overview of the market opportunities for Idiopathic Pulmonary Fibrosis (IPF).